Pure Global
NCT06223204

GLEAM: Noninvasive Glucose Measurement Using Impedance Tomography

GLEAM: Noninvasive Glucose Measurement Using Impedance Tomography - a Pilot Project
Insel Gruppe AG, University Hospital Bern·ClinicalTrials.gov·otherNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Diabetes Mellitus
Drug/Device/Intervention
Controlled euglycemia, hypoglycemia and hyperglycemia
Study type
Interventional
Intervention type
other
Sponsor & location
Primary sponsor
Insel Gruppe AG, University Hospital Bern
Location
Bern, Switzerland
Timeline & enrollment
Phase
N/A
Start date
Feb 01, 2024
End date
Jan 31, 2025
Enrollment
16 participants
Primary outcome

Change of the electrical impedance tomography (EIT) signal of the thoracic region across the glycemic trajectory.

Summary

The GLEAM study aims at assessing the potential of electrical impedance tomography (EIT) for
 noninvasive glucose measurement.

ICD-10 classifications
Diabetes mellitusUnspecified diabetes mellitusOther specified diabetes mellitusUnspecified diabetes mellitus without complicationsUnspecified diabetes mellitus with unspecified complications
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06223204
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06223204 through Pure Global AI's free database. This phase not specified trial is sponsored by Insel Gruppe AG, University Hospital Bern and is currently Not yet recruiting. The study focuses on Diabetes Mellitus. Target enrollment is 16 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.